The European Commission approved Ronapreve and Regkirona preparations based on monoclonal antibodies for the treatment of caused by coronavirus disease. This was reported by the European Medicine Agency (EMA), writes TASS.
“Ronapreve and Regkirona are now approved in the EU, – reported in the agency. – European Commission issued registration certificates for these drugs on November 12.
Earlier, the EMA Committee for Medicines for a person issued a positive conclusion for these drugs.
Ronapreve, produced by the German company Roche, is a mixture of Casirivimab and imgemab – synthetic copies of antibodies produced by a person after coronavirus infection, and is recommended for patients who do not need oxygen support. REGKIRONA preparation is produced by the Celltrion Highcast and is intended for patients with a risk of severe course caused by coronavirus infection.